← Back to Clinical Trials
Recruiting NCT07140601

NCT07140601 Environmental Pollutants and Neurological Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07140601
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Cerebrovascular Disorders
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2025-08-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2025-08-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming. Brain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence. Given the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.

Eligibility Criteria

Inclusion Criteria: * 18 years of age or older; * Able to give informed consent to participate in the research. Exclusion Criteria: * Refusal to participate. * Pregnant or breastfeeding woman.

Contact & Investigator

Central Contact

Runting Li, MD

✉ tt18080lrt@163.com

📞 +86 15753166690

Frequently Asked Questions

Who can join the NCT07140601 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cerebrovascular Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07140601 currently recruiting?

Yes, NCT07140601 is actively recruiting participants. Contact the research team at tt18080lrt@163.com for enrollment information.

Where is the NCT07140601 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07140601 clinical trial?

NCT07140601 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology